Validation of Aspiration Markers in Intubated Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this interventional study is to test Quinine as marker of aspiration (endotracheal tube \[ETT\] cuff leakage) in mechanically ventilated, critically ill patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Broncho-aspiration (BA) in Adult Subjects During Their ICU Stay

NCT05284084

Bronchial Aspiration

COMPLETED NA

The Effects of Endotracheal Suctioning on Pain and Serum Markers

NCT06692400

Intensive Care Unit ICU Intubation Critical Illness +12 more

RECRUITING NA

Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment (BY2001/M1-007)

NCT00074906

Pneumonia

COMPLETED PHASE3

Oral Suction Intervention to Reduce Aspiration and Ventilator Events: NO-ASPIRATE

NCT02284178

Respiratory Failure

COMPLETED NA

Pressure Support and Positive End Expiratory Pressure During Spontaneous Breathing Trial

NCT03861117

Critically Ill Adult Patients With Difficult Weaning

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

At present there is no standard method for the evaluation of in vivo cuff leak and aspiration. Most of the tested techniques have major pitfalls that render their routine application infeasible. Lacking a practical and reliable marker, any possible intervention aimed at improving cuff seal and ETT performance in order to reduce VAP occurrence is going to be hindered by the inability to truly evaluate its efficacy. Radio-labeled markers are expensive, expose the patient to considerable radiological risk, and require transport to a radiological department, which would expose critically ill patients to additional risk. Dyes have the potential to give useful information about the presence of a cuff leak, but due to persistent staining of secretions, they do not allow continuous monitoring of aspiration. Amylase detection could be a good marker of aspiration, but its ability to detect aspiration is poor even when compared to pepsin. Pepsin and bile acids have the potential to detect some of the aspirations and cuff leaks that happen daily in mechanically ventilated patients, but due to their gastrointestinal nature, they do not offer any kind of information about aspiration of contaminated oropharyngeal secretions. With this research protocol, the investigators would like to validate the use of Quinine suspended in sterile water as marker for determining cuff leakage and aspiration events in an ICU population. Quinine is compound commonly used in food manufacturing. His pharmacokinetic and -dynamic has extensively been studied. The chemical structure of this molecule allows the detection up to pico-molar concentration by spectrophotometry.

The investigators will challenge the oropharyngeal cavity with a known concentration of Quinine suspended in sterile water. The investigators hypothesized that the detection by spectrophotometry of the same substance in the tracheal secretions will prove aspiration.

The investigators specific aims are:

1. To quantify the measurements of Quinine in the tracheal sample and compare with the measurements of Quinine in the oral sample.
2. To assess association between the amount of oropharyngeal aspiration and the development of upper and lower respiratory complications (i.e. ventilator associated pneumonia \[VAP\], tracheobronchitis, ventilator-associated events, acute respiratory distress syndrome \[ARDS\], etc.).
3. To determine patient's risk factors associated with oropharyngeal aspiration. The introduction of this new, safe and inexpensive markers for evaluating ETT cuff performance and for detecting aspiration will improve the design of future studies aimed at VAP prevention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumonia Aspiration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aspiration Markers

Aspiration marker solution will be composed as following: Quinine 83 mg/L suspended in sterile water. After enrollment patients will be challenged with 5 mL of the study solution nebulized in the retropharyngeal space twice a day for two consecutive days.

Group Type EXPERIMENTAL

Aspiration Marker

Intervention Type DRUG

Instillation of Quinine suspended in sterile water in the retropharyngeal space of intubated ICU admitted patients for two consecutive days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aspiration Marker

Instillation of Quinine suspended in sterile water in the retropharyngeal space of intubated ICU admitted patients for two consecutive days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Admission to Surgical ICUs (MGH Ellison 4 or Blake 12)
* Patients expected to be intubated for at least 48 hours or longer from the time of enrollment.

Exclusion Criteria

* High PEEP requirement at enrollment (PEEP higher than 8 cmH2O)
* Diagnosis of ARDS (any severity)
* Status asthmatics
* Current or past participation in another interventional trial conflicting with the present study
* Pregnant women
* Prisoner status
* Patients who had partial or total gastrectomy.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No